|Overview of B Cells and T Cells |
B Cells and T-Cells and Autoimmunity
|B Cells and T Cells and Systemic Sclerosis|
T cells are white blood cells that help stimulate an immune response to infections. In the thymus gland, lympohocytes are matured into T cells. Sometimes T cells become overactive, which is suspected as being part of the process that leads to autoimmune diseases. (Also see Causes of Scleroderma, What is Scleroderma?, Types of Scleroderma, and Systemic Sclerosis)
B Cells and T Cells.The white blood cells involved in the acquired immune response are called 'lymphocytes'. There are two main types of lymphocytes - B cells and T cells. B and T lymphocytes are made in the bone marrow, like the other blood cells. They have to fully mature before they can help in the immune response. T cells travel through the blood stream to the thymus gland where they become fully developed. Once they are fully mature, they travel to the spleen and lymph nodes, ready to fight infection. Cancer Research UK.
Thymus. The thymus is a ductless gland located in the upper anterior portion of the chest cavity. It is most active during puberty, after which it shrinks in size and activity in most individuals and is replaced with fat. The thymus plays an important role in the development of the immune system in early life, and its cells form a part of the body's normal immune system. Wikepedia.
Checkpoints for Autoreactive B Cells in Peripheral Blood of Lupus Patients Assessed By Flow Cytometry. This assay will enable studies to identify potential genetic or environmental factors affecting B cell tolerance checkpoints in health and disease and permit monitoring of the B cell response to therapeutic interventions. Wiley Online Library, 04/08/2016.
Intrarenal macrophage infiltration induced by T cells is associated with podocyte injury in lupus nephritis patients. The present study provides possible links between intrarenal T cells, osteopontin, macrophages with reduced podocyte–nephrin and podocytopathy in systemic lupus erythematosus. PubMed, Lupus, 05/04/2016. (Also see Symptoms and Complications of Lupus)
Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus. In patients with SLE increased numbers of autoreactive Th17 cells have been documented, and Th17 cells appear to be responsible for tissue inflammation and damage. PubMed, Front Immunol, 2015 Nov 30;6:610.
Renal involvement in primary Sjögren's syndrome (SS). The prevalence of renal SS, its presentation, likely pathogenesis and treatment is reviewed in this article. PubMed, Rheumatology (Oxford), 2015 Sep;54(9):1541-8. (Also see Sjögren's Syndrome)
Update on the immunobiology of Sjögren's (pSS) syndrome. Progress made during the last few years on the pathogenesis of pSS has been mirrored by clinical trials directed at inhibiting cytokines, B, or T cell responses. PubMed, Current Opinion in Rheumatology, 08/04/2015. (Also see Sjögren's Syndrome Research)
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor (BAFF) receptor in patients with primary Sjogren's syndrome (pSS). Targeting BAFF with belimumab is successful in normalizing B cell frequency, phenotype and functions in pSS. PubMed, Rheumatology (Oxford), 03/03/2015. (Also see Treatments for Symptoms of Sjogren's Syndrome)
Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis. The onset of RA is characterized by higher percentages and absolute numbers of naïve B cells and could represent a promising biomarker of outcome. PubMed, BMC Immunol, 2014 Sep 4;15(1):28. (Also see Rheumatoid Arthritis)
Implication of Epstein-Barr virus (EBV) infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjogren's syndrome (SS). Active EBV infection is selectively associated with ectopic lymphoid structures in salivary glands of Sjogren's syndrome and appears to contribute to local growth and differentiation of disease-specific autoreactive B-cells. PubMed, Arthritis Rheumatol, 2014 May 28. (Also see Sjogren's Syndrome)
Autoimmune Aspects of Type 2 Diabetes Mellitus (T2DM) — A Mini–Review. The review focuses on autoimmune involvement in T2DM, with an emphasis on latent autoimmune diabetes of the adult, the humoral immune response and specifically the role of B and T cells as links between inflammatory and autoimmune reactions. Gerontology 2014;60:189-196. (Also see Diabetes)
Natural killer (NK) cells in human autoimmune disorders. NK cells are innate lymphocytes that play a critical role in early host defense against viruses. PubMed, Arthritis Res Ther, 2013 Jul 11.
Frequency of circulating topoisomerase–I–specific CD4 T cells predicts presence and progression of interstitial lung disease (ILD) in scleroderma. Topo–I–specific T cells can be reliably quantified in the peripheral blood of patients with scleroderma, exhibit a pro–inflammatory Th17 phenotype, and predict progression of ILD. BioMed Central, Arthritis Research & Therapy, 05/04/2016. (Also see Pulmonary Fibrosis)
Connective tissue diseases: Nucleosomes and systemic sclerosis (SSc). New observations suggest that nucleosomes can mediate both IgG production and B–cell proliferation, via Toll–like receptor signalling, and thereby affect the pathogenesis of SSc. Nature Reviews Rheumatology, 02/04/2016.
B lymphocytes in systemic sclerosis (SSc): Abnormalities and therapeutic targets. Altered B–cell function may result in tissue fibrosis, as well as autoimmunity and although further studies and greater understanding are needed, B cells are potential therapeutic targets in SSc. Wiley Online Library, 01/04/2016.
Systemic sclerosis: New evidence re-enforces the role of B cells. Recent evidence suggests that B cells are also likely to contribute in the pathogenesis of the disease. PubMed, Autoimmun Rev, 10/21/2015.
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. These data provide further evidence of B-cell involvement in the pathogenesis of scleroderma and targeting B cells may be a promising treatment for scleroderma patients. PubMed, Clin Exp Rheumatol, 2015 Sep-Oct;33 Suppl 91(4):160-167. (Also see Clinical Trials)
Rituximab in diffuse cutaneous systemic sclerosis (SSc): should we be using it today? We summarize the therapeutic use of rituximab in SSc and the basic science evidence suggesting that B cells and autoantibodies are the primary drivers of fibrosis in skin and lung tissue. PubMed, Rheumatology (Oxford), 07/01/2015. (Also see Scleroderma Clinical Trials)
Involvement of CD161+ Vδ1+ yδ T cells in systemic sclerosis (SSc): association with interstitial pneumonia (IP). The small proportion and the altered cell functions of CD161+ Vδ1+ yδ T cells among peripheral blood mononuclear cells in SSc patients play a role in the pathogenesis of IP and may play a regulatory role in pathogenesis. PubMed, Rheumatology (Oxford), 2014 Jun 27.
Augmented Inducible costimulator (ICOS) expression in patients with early diffuse cutaneous systemic sclerosis (dcSsc). Augmented ICOS signalling may contribute to the pathogenesis of Systemic Sclerosis (SSc) during early progressive disease. Soluble ICOS levels may be used as a serum marker for the activity and severity of SSc. PubMed, Rheumatology, 2013 Feb;52(2):242-51.
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Rituximab (RTX) may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, a finding that supports a disease-modifying role of RTX in Systemic Sclerosis (SSc). Arthritis Res Ther, 2012 Jun 14;14(3):R145. (Also see Scleroderma Treatments and Clinical Trials)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, Volunteer, or Donate.
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.